Menopausal hormone therapy and cervical cancer: A current view of the problem


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To carry out a systematic analysis of the results of investigations of whether menopausal hormone therapy (MHT) can be used in patients who have been diagnosed with cervical cancer (CC) and/or completed treatment. Material and methods. The article includes the data of foreign articles published in Pubmed and Medline the past 20 years. Results. This paper presents the results of retrospective studies, the purpose of which was to determine the rate of recurrent CC in women receiving MHT compared with the control group. Conclusion. On the one hand, menopausal symptoms developing after surgery (after both panhysterectomy and organ-sparing surgery) and radiation with or without systemic (cytostatic) treatments continue to remain relevant to patients who have successfully completed treatment for squamous cell cancer of the cervix. On the other hand, clinicians need to have clinical protocols regulating the basic criteria for prescribing MHT.

Full Text

Restricted Access

About the authors

Oksana Vladimirovna Yakushevskaya

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: ykushox83@mail.ru
Ph.D., scientific employee of the department of gynecological endocrinology

Svetlana Vladimirovna Yureneva

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: syureneva@gmail.com
MD, professor, leading researcher of the department of gynecological endocrinology

Grigory Nikolaevich Khabas

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: g_khabas@oparina4.ru
Candidate of Medical Science, Leading Researcher, Head of the Department of Innovative Oncology and Gynecology

Anna Eduardovna Protasova

St. Petersburg State University; V.A. Almazov North-West Research Center

Email: protasova1966@yandex.ru
MD, Professor, Department of Oncology, Medical Faculty; Professor of the Department of Obstetrics and Gynecology

References

  1. O’Donnel R.L., Clement K.M., Edmondson R.J. Hormone replacement therapy after treatment for a gynecological malignancy. Curr. Opin. Obstet. Gynecol. 2016; 28(1): 32-41
  2. Юренева С.В., Ильина Л.М., Якушевская О.В. Менопаузальная гормональная терапия в постменопаузе: качество жизни сегодня и в долгосрочной перспективе. Гинекология. 2016; 18(1): 24-9
  3. Baber R., Panay N., Fenton A.; IMS Writing Group. 2016 IMS Recommendations on on women’s midlife health and menopause hormone therapy. Climacteric. 2016; 19(2): 109-50.
  4. Armeni E., Lambrinoudaki I., Ceausu I., Depypere H., Mueck A., Pérez-Lopez F.R. et al. Maintaining postreproductive health: A care pathway from the European Menopause and Andropause Society (EMAS). Maturitas. 2016; 89: 63-72.
  5. Каприна А.Д., Старинский В.В., Петрова Г.В., ред. Злокачественные новообразования в России в 2014 году (заболеваемость и смертность). М.: МНИОЦ им. П.А. Герцена - филиал ФГБУ «НМИРЦ» Минздрава России; 2016. [Kaprina A.D., Starinsky V.V., Petrova G.V., ed. Malignant neoplasms in Russia in 2014 (morbidity and mortality). Moscow: MNIOTs im. P.A. Gertsena - filial FGBU «NMIRTs» Minzdrava Rossii; 2016. (in Russian)]
  6. Хохлова С.В., Коломиец Л.А., Кравец О.А., Крикунова Л.И., Морхов К.Ю., Нечушкина В.М., Новикова Е.Г., Телетаева Г.М., Урманчеева А.Ф., Тюляндина А. С. Практические рекомендации по лекарственному лечению рака шейки матки. Злокачественные опухоли. 2016; 4(Спецвыпуск 6): 147-60. [Khokhlova S.V., Kolomiets L.A., Kravets O.A., Krikunova L.I., Morkhov K.Yu., Nechushkina V.M., Novikova E.G., Teletaeva G.M., Urmancheeva A.F., Tyulyandina A.S. Practical recommendations for the treatment of cervical cancer Zlokachestvennyie opuholi. 2016; 4 (Special Issue 6): 147-60. (in Russian)]
  7. Gubbala K., Laios A., Gallos I., Pathiraja P., Haidar K., Ind T. Outcomes of ovarian transposition in gynecological cancers: a systematic review and metaanalysis. J Ovarian Res. 2014; 7: 69.
  8. Buekers T.E., Anderson B., Sorosky J.I., Buller R.E. Ovarian function after surgical treatment for cervical cancer. Gynecol. Oncol. 2001; 80(1): 85-8.
  9. NCCN. Guidelines Version 1. Cervical Cancer. 2016.
  10. Colombo N., Carinelli S., Colombo A., Marini C., Rollol D., Sessa C. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2012; 23(Suppl. 7): 27-32.
  11. Parazzini F., La Vecchia C., Negri E., Franceschi S., Moroni S., Chatenoud L., Bolis G. Case control study of oestrogen replacement therapy and risk of cervical cancer. BMJ. 1997; 315(7100): 85-8.
  12. Ploch E. Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol. Oncol. 1987; 26(2): 169-77.
  13. Hunt K., Vessey M., McPherson K., Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br. J. Obstet. Gynaecol. 1987; 94(7): 620-35.
  14. Adami H.O., Persson I., Hoover R., Schairer C., Bergkvist L. Risk of cancer in women receiving hormone replacement therapy. Int. J. Cancer. 1989; 44(5): 833-9.
  15. Persson I., Yuen J., Bergkvist L., Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy--long-term follow-up of a Swedish cohort. Int. J. Cancer. 1996; 67(3): 327-32.
  16. Lacey J.V. Jr., Brinton L.A., Barnes W.A., Gravitt P.E., Greenberg M.D., Hadjimichael O.C. et al. Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix. Gynecol. Oncol. 2000; 77(1): 149-54.
  17. Dallenbach-Hellweg G., Poulsen G. Atlas of histopathology of the cervix uteri. Berlin: Springer; 1990.
  18. Ibeanu O., Modesitt S.C., Ducie J., von Gruenigen V., Agueh M., Fader A.N. Hormone replacement therapy in gynecologic cancer survivors: Why not? Gynecol. Oncol. 2011; 122(2): 447-54.
  19. Jaakkola S., Pukkala E., Lyytinen H.K., Ylikorkala O. Postmenopausal estradiolprogestagen therapy and risk for uterine cervical cancer. Int. J. Cancer. 2012; 131(4): Е537-43.
  20. Panay N., Hamoda H., Arya R., Savvas M.; British Menopause Society and Women’s Health Concern. The 2013 British Menopause Society and Women’s Health Concern recommendations on hormone replacement therapy. Menopause Int. 2013; 19(2): 59-68.
  21. Singh P., Oehler M.K. Hormone replacement after gynaecological cancer. Maturitas. 2010; 65(3): 190-7.
  22. Hinds L., Price J. Menopause, hormone replacement and gynaecological cancers. Menopause Int. 2010; 16(2): 89-93.
  23. Biliatis I., Thomakos N., Rodolakis A., Akrivos N., Zacharakis D., Antsaklis A. Safety of hormone replacement therapy in gynaecological cancer survivors. J. Obstet. Gynaecol. 2012; 32(4): 321-5.
  24. Sjoquist K.M., Martyn J., Edmondson R.J., Friedlander M.L. The role of hormonal therapy in gynecological cancers-current status and future directions. Int. J. Gynecol Cancer. 2011; 21(7): 1328-33.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies